Assessing if Westinghouse Electric Company's (WST) shares are underpriced at a value of $200.

Assessing if Westinghouse Electric Company's (WST) shares are underpriced at a value of $200.

Yo, Check Out these News Bits!

West Pharma, the global drug and healthcare product provider, recently crushed analysts' expectations in Q4, reporting a $749 million revenue and an EPS of $1.82, outpacing their previous year's figures of $740 million and $1.73. However, their future guidance came up short, leading to a stock price slip after the announcement. Meanwhile, check out What's Next For U.S. Steel Stock After A Mixed Q4?

West Pharma's stock, WST, has been having a rough year, dropping 43% since the start of 2024 and underperforming the S&P 500 by a wide margin. The company's woes can be traced back to lower profits from their generics and biologics segments. For those seeking some stability, the High-Quality Portfolio might be your new BFF. This badass collection of stocks has outperformed the S&P 500 by an impressive 91% since its birth, bringing home the big bucks.

Want the nitty-gritty on West Pharma's Q4 performance? Their sales revved up 2.3% year over year, with proprietary products seeing a 3.4% spike and contract-manufactured products dropping by a disappointing 2.5%. The company's gross profit margin dropped by 150 basis points, and the operating margin dipped by 10 basis points, impacting their earnings. Looking ahead, West Pharma expects 2025 sales and earnings of $2.89 billion and $6.10, respectively, falling short of market expectations.

West Pharma's stock took a nosedive following the earnings announcement, diving 38%. Their stock's performance has been a rollercoaster in recent years, delivering hefty returns of 66% in 2021, but dipping down to -50% in 2022, then bouncing back to 50% in 2023, and finally tumbling back down by 7% in 2024.

The High-Quality Portfolio, however, has exhibited rock-solid stability, delivering reliable returns while trouncing the S&P 500. But why does it perform so well? It's all about the fundamentals and a smart approach to risk management.

As economy-related uncertainties linger, including the prospect of interest rate cuts and ongoing trade tensions, will West Pharma continue its ups and downs? Or is there hope for a comeback in 2025? We reckon WST stock is currently a steal, trading at just 5.1x trailing revenue compared to its average PR/Sales ratio of 9.2x. But before diving in, don't forget to consider the numbers of West Pharma's Peers in the industry.

Want to get in on the action? Give the Trefis Market-Beating Portfolios a shot!

For more price predictions, hop on over to the Trefis Price Estimates.

FYI: The Inside Scoop On West Pharma's Underperformance

Why West Pharma's stock hasn't kept pace with the S&P 500 can be attributed to a couple of factors:

1. Analyst Disappointment: West Pharma's earnings forecast fell short of market expectations, sending their stock price plummeting.
2. Market Expectations: The market had higher expectations for West Pharma's earnings growth, which weren't met, leading to a negative investor reaction.

High-Quality Portfolio's Secret Sauce

The High-Quality Portfolio, as detailed in the Capitalist Letters newsletter, has notched up impressive numbers in recent times, delivering a 51% return despite the S&P 500's 24% gain. The key reasons for its success include:

1. Competitive Stronghold: The portfolio invests heavily in companies with strong, sustainable market positions.
2. Financial Stability: It focuses on companies with solid financials and growth potential, ensuring long-term profitability.
3. Risk Management: The portfolio employs conservative valuation techniques to manage risk, allowing for steady growth over time.
4. Informed Decisions: The portfolio manager conducts thorough research and often publishes insights to help make well-informed investment choices.

These strategies have positioned the High-Quality Portfolio alongside market-beating returns while keeping risk levels in check.

West Pharma's Q4 revenue surpassed expectations, reaching $749 million, but their stock, WST, experienced a decline due to lower-than-projected future guidance. The company's woes, including a drop in profits from their generics and biologics segments, have contributed to a rough year for WST, underperforming the S&P 500 significantly.

In contrast, the High-Quality Portfolio, which has been performing exceptionally well, has managed to outperform the S&P 500 by a staggering 91% since its inception. This portfolio has been able to benefit from its focus on companies with strong financials, sustainable market positions, and conservative risk management strategies.

By the end of 2024, West Pharma's stock had fallen 43% from its yearly start, underperforming the S&P 500. Analyst disappointment and high market expectations for West Pharma's earnings growth might have contributed to its underperformance.

Despite these challenges, West Pharma's stock is currently trading at a lower multiple than its historical average, offering a potential opportunity for investors. However, it's crucial to consider the performance of West Pharma's peers amidst the ongoing economic uncertainties before making any investment decisions.

Read also: